SOLESENCE, INC. — Director's Dealing 2018

May 25, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NANOPHASE TECHNOLOGIES Corp (NANX)
CIK: 0000883107
Period of Report: 2014-09-03

Reporting Person: Vincent George A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-09-03	Common Stock	P	20618	$0.51	Acquired	20618	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-23	Common Stock (right to purchase)	$0.82	A	10000	Acquired	2028-05-23	Common Stock (10000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Common Stock (right to purchase)	$1.36	2021-01-31	Common Stock (12000)	12000	Direct
Deferred Common Stock	$		Common Stock (2250)	12652	Direct
Common Stock (right to purchase)	$0.30	2022-08-07	Common Stock (12000)	12000	Direct
Common Stock (right to purchase)	$0.415	2023-02-14	Common Stock (10000)	10000	Direct
Common Stock (right to purchase)	$0.52	2024-02-13	Common Stock (10000)	10000	Direct
Common Stock (right to purchase)	$0.44	2025-02-18	Common Stock (9000)	9000	Direct
Common Stock (right to purchase)	$0.42	2026-02-23	Common Stock (8100)	8100	Direct
Common Stock (right to purchase)	$0.90	2026-11-17	Common Stock (2250)	2250	Direct
Common Stock (right to purchase)	$1.05	2026-11-17	Common Stock (2250)	2250	Direct
Common Stock (right to purchase)	$1.18	2026-11-17	Common Stock (2250)	2250	Direct
Common Stock (right to purchase)	$0.84	2026-11-17	Common Stock (2250)	2250	Direct
Common Stock (right to purchase)	$1.85	2026-11-17	Common Stock (2250)	2250	Direct
Common Stock (right to purchase)	$1.10	2026-11-17	Common Stock (2250)	2250	Direct
Common Stock (right to purchase)	$0.99	2026-11-17	Common Stock (2250)	2250	Direct
Common Stock (right to purchase)	$0.68	2027-02-21	Common Stock (10000)	10000	Direct

Footnotes

F1: These shares of common stock were purchased in the open market during an open trading window for Company officers and directors. The Form 4s filed by the reporting person after September 3, 2014 and prior to the date of this Form 4 did not reflect these shares as being owned by the reporting person.

F2: Subject to certain rights and restrictions, beginning on this date, options vest in three equal annual installments.

F3: Each share of deferred common stock represents a right to receive one share of common stock.

F4: The deferred common stock becomes payable upon the reporting person's termination of service as a director of the Company.

F5: Pursuant to such plan, the reporting person elected to defer receipt of such shares and receive a cumulative total of 12,652 shares of deferred common stock which will all be accounted for under the Company's Non-Employee Director Deferred Compensation Plan.

F6: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued with exercise prices equal to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99.